Quantum Genomics S.A. (ALQGC.PA)
Quantum Genomics S.A. operates in the Biotechnology industry of the Healthcare sector, headquartered in Paris, FR. The stock last traded at $0.07, up 0.00% on the session, giving a market capitalisation of $5.0M. Its beta of 0.16 implies it has historically moved less than the broad market.
Quantum Genomics S.A., a biopharmaceutical firm established in Paris, France, in 2005, focuses on creating treatments for cardiovascular ailments. Its therapeutic approach utilizes the brain aminopeptidase A inhibition (BAPAI) platform, primarily addressing high blood pressure (hypertension) and heart failure. The company's key asset, firibastat, is currently undergoing a crucial Phase III study as a standalone therapy for hypertension and is also in clinical trials for heart failure. Additionally, Quantum Genomics is progressing QGC011 for hypertension in combination therapy, and further developing QGC006 and QGC606 to target both hypertension and heart failure.
Quantum Genomics S.A. is most often compared with the following Healthcare names: